Please login to the form below

Not currently logged in
Email:
Password:

AZ's phase III RA trial underway

AstraZeneca has announced the beginning of phase III clinical trial development for rheumatoid arthritis treatment fostamatinib

AstraZeneca (AZ) has announced the beginning of phase III clinical trial development for rheumatoid arthritis (RA) treatment fostamatinib.

The trial will study the effects of fostamatinib – developed as an oral syk inhibitor – in patients with previously inadequate response to disease-modifying anti-rheumatic drugs (DMARDs).

Syk is a form of tyrosine kinase protein that can lead to the inflammatory conditions of RA when functioning abnormally. Fostamatinib is designed to block the function of syk, halting progression of the disease.

Phase III development of the drug will see three trials assessing its efficacy and safety, including two 12-month studies examining the effect of fostamatinib on patients responding inadequately to DMARDs.

As published in the New England Journal of Medicine, a previous phase II programme demonstrated positive results for the drug, then known as R788, in RA patients who failed to respond adequately to current treatments.

Commenting on the development of fostamatinib, Anders Ekblom, AZ's executive vice president of global medicines development, said: "Patients with rheumatoid arthritis currently have limited treatment options after they stop responding adequately to DMARDs or anti-TNF therapy, and we are hopeful that fostamatinib may represent a novel alternative for patients to help manage their condition beyond this stage."

Fostamatinib was initially developed by Rigel Pharmaceuticals, with AZ purchasing rights to further develop and commercialise the drug in February 2010.

29th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....